# A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

> **NCT04385433** · PHASE3 · TERMINATED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** EXPERIMENTAL ARM
- **OTHER:** CONTROL GROUP
- **RADIATION:** Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)

## Key facts

- **NCT ID:** NCT04385433
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-04
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Not enough patients enrolled
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385433, "A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04385433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*